ShurrawS., TonelliM.Statins for treatment of dyslipidemia in chronic kidney disease.Perit Dial Int2006; 26: 523–39.
2.
AthyrosV.G., MikhailidisD.P., PapageorgiouA.A., SymeonidisA.N., PehlivanidisA.N., BouloukosV.I.The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study.J Clin Pathol2004; 57: 728–34.
3.
AthyrosV.G., ElisafM., PapageorgiouA.A., SymeonidisA.N., PehlivanidisA.N., BouloukosV.I.; GREACE Study Collaborative Group. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.Am J Kidney Dis2004; 43: 589–99.
4.
AthyrosV.G., MikhailidisD.P., LiberopoulosE.N., KakafikaA.I., KaragiannisA., PapageorgiouA.A.Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study.Nephrol Dial Transplant2006 (23 September 2006; epub ahead of print, doi: 10.1093/ndt/gfl538).
